Categories: Life Science | Format :
The Global High Potency Active Pharmaceutical Ingredients Market size is estimated to reach $21.41 Billion by 2026, growing at a CAGR of 9.1% over the forecast period of 2021-2026.
HPAPIs are pharmacologically active compounds with biological activity at very low concentrations, such as a daily therapeutic dosage of 10 mg or an occupational exposure limit (OEL) of 10 g/m3 at an eight-hour time-weighted average. The growing number of individuals affected by cancer is regarded as one of the most severe health risks.
The number of people infected with COVID-19 is quickly increasing, and several nations have allowed the use of high-potency antiviral medications. Remdesivir, for example, has been approved for COVID-19. The medicine is now licensed in the United States, the United Kingdom, India, Singapore, Israel, the European Union, Taiwan, and Japan to treat SARS-CoV-2.
Many completed medication products and raw materials for drug manufacturing are imported from Europe, India, and China, including active pharmaceutical components (APIs). However, the COVID-19 pandemic has resulted in shortages of active pharmaceutical ingredients and completed pharmaceutical products.
Antibiotics, antihypertensive, and antivirals come from China, a key source of active pharmaceutical ingredients. Unfortunately, many companies in China had to stop temporarily due to the pandemic8, resulting in a halt in the production of active medicinal components and finished products.
Increasing demand for Oncology Drugs drives the market demand
High Potency Active Pharmaceutical Ingredients are particularly effective and pharmacologically active compounds. They have an exact mechanism of action and are effective even at modest daily therapeutic dosages.
High Potency Active Pharmaceutical Ingredients can target specific disease cells and are thus employed in high-potency medication formulations. HPAPIs have a lot of potential in cancer target therapy because of their target release features. The global incidence of cancer is increasing at an alarming rate.
Rising Evolution of Industry Standards is set to limit the market growth.
The constant growth of industry standards, technologies, and regulations is a challenge for CMOs that provide High Potency Active Pharmaceutical Ingredient production services. Companies interested in entering this market must embrace this modern technology, which entails large expenditures.
By product, the market for biotech is estimated to grow at the highest CAGR during the forecast period.
Based on Product, Global High Potency Active Pharmaceutical Ingredients Market is segmented into Synthetic and Biotech. Many synthetic compounds are also projected to become patent-expired in the future years, boosting industry growth. In addition, the Japanese government has promoted the use of generic medications to lower overall healthcare costs and patient financial burdens.
As a result, biotech is the fastest-growing with a CAGR of 9.6% over 2021-2026. Drug compounds generated by molecular approaches such as recombinant DNA technology make up the majority of biotech High Potency Active Pharmaceutical Ingredients.
Because of the more significant income associated with biotech-related API, the business is extremely attractive, attracting substantial participants. Furthermore, significant investments in the biotechnology and biopharmaceutical industries might be ascribed to the biotech segment’s rise. This opens the door to developing novel compounds that assist in treating illnesses like cancer.
By Application, the market for Glaucoma is estimated to grow at the highest CAGR during the forecast period.
By Applications, Oncology dominated the market in 2020. The growth in cancer incidence is a primary reason driving the demand for High Potency Active Pharmaceutical Ingredients. According to the World Health Organization, there were 18 million cancer cases worldwide in 2018, with 8.5 million cases among women and 9.5 million cases among men.
With the rising prevalence in established and emerging nations, the glaucoma sector is expected to increase exponentially with a CAGR of 9.6% during 2021-2026. In addition, high-potency compounds are required to treat diseases like HIV, and demand for these molecules is predicted to rise as the number of HIV patients rises.
Furthermore, the rising occurrence of infectious disorders associated with antibiotic resistance will likely propel the High Potency Active Pharmaceutical Ingredients market forward.
The Asia Pacific to account for the largest market share during the forecast period
North America dominated the Global High Potency Active Pharmaceutical Ingredients Market with a share of 35.9% in 2020. This might be linked to the region’s growing demand for High Potency Active Pharmaceutical Ingredients and essential manufacturers, and superior technology infrastructure.
However, Asia Pacific is the fastest-growing over 2021-2026. This is owing to rising healthcare expenditure in the region.
The report “Global High Potency Active Pharmaceutical Ingredients Market” by Research Informatic covers an in-depth detailed analysis for the following segments covered under the scope.
Key Players in Global High Potency Active Pharmaceutical Ingredients Market consist of BASF SE, Corden Pharma, Dr Reddy’s Laboratories, Pfizer Inc, Sun Pharmaceuticals, Sanofi S.A, Merck & Co, Novrartis, Roche, Cipla Inc among others.
In July 2020, Albany Molecular Research, Inc. (AMRI) announced a collaboration with BioSig Technologies, Inc. to deliver merimepodib to produce antivirals to treat SARS-CoV-2. This supply arrangement allows the firm to remain competitive and make more income.
Global High Potency Active Pharmaceutical Ingredients Market Growth, Trend and Forecast 2021-2028
Chapter 1 High Potency Active Pharmaceutical Ingredients Market Overview
1.1 Product Overview and Scope of High Potency Active Pharmaceutical Ingredients
1.2 High Potency Active Pharmaceutical Ingredients Market Segmentation by Type
1.2.1 Global Production Market Share of High Potency Active Pharmaceutical Ingredients by Type in 2020
1.2.1 Type 1
1.2.2 Type 2
1.2.3 Type 3
1.3 High Potency Active Pharmaceutical Ingredients Market Segmentation by Application
1.3.1 High Potency Active Pharmaceutical Ingredients Consumption Market Share by Application in 2020
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 High Potency Active Pharmaceutical Ingredients Market Segmentation by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India
1.5 Global Market Size (Value) of High Potency Active Pharmaceutical Ingredients (2014-2028)
Chapter 2 Global Economic Impact on High Potency Active Pharmaceutical Ingredients Industry
2.1 Global Macroeconomic Environment Analysis
2.1.1 Global Macroeconomic Analysis
2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions
Chapter 3 Global High Potency Active Pharmaceutical Ingredients Market Competition by Manufacturers
3.1 Global High Potency Active Pharmaceutical Ingredients Production and Share by Manufacturers (2020 and 2020)
3.2 Global High Potency Active Pharmaceutical Ingredients Revenue and Share by Manufacturers (2020 and 2020)
3.3 Global High Potency Active Pharmaceutical Ingredients Average Price by Manufacturers (2020 and 2020)
3.4 Manufacturers High Potency Active Pharmaceutical Ingredients Manufacturing Base Distribution, Production Area and Product Type
3.5 High Potency Active Pharmaceutical Ingredients Market Competitive Situation and Trends
3.5.1 High Potency Active Pharmaceutical Ingredients Market Concentration Rate
3.5.2 High Potency Active Pharmaceutical Ingredients Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion
Chapter 4 Global High Potency Active Pharmaceutical Ingredients Production, Revenue (Value) by Region (2014-2021)
4.1 Global High Potency Active Pharmaceutical Ingredients Production by Region (2014-2021)
4.2 Global High Potency Active Pharmaceutical Ingredients Production Market Share by Region (2014-2021)
4.3 Global High Potency Active Pharmaceutical Ingredients Revenue (Value) and Market Share by Region (2014-2021)
4.4 Global High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
4.5 North America High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
4.6 Europe High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
4.7 China High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
4.8 Japan High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
4.9 Southeast Asia High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
4.10 India High Potency Active Pharmaceutical Ingredients Production, Revenue, Price and Gross Margin (2014-2021)
Chapter 5 Global High Potency Active Pharmaceutical Ingredients Supply (Production), Consumption, Export, Import by Regions (2014-2021)
5.1 Global High Potency Active Pharmaceutical Ingredients Consumption by Regions (2014-2021)
5.2 North America High Potency Active Pharmaceutical Ingredients Production, Consumption, Export, Import by Regions (2014-2021)
5.3 Europe High Potency Active Pharmaceutical Ingredients Production, Consumption, Export, Import by Regions (2014-2021)
5.4 China High Potency Active Pharmaceutical Ingredients Production, Consumption, Export, Import by Regions (2014-2021)
5.5 Japan High Potency Active Pharmaceutical Ingredients Production, Consumption, Export, Import by Regions (2014-2021)
5.6 Southeast Asia High Potency Active Pharmaceutical Ingredients Production, Consumption, Export, Import by Regions (2014-2021)
5.7 India High Potency Active Pharmaceutical Ingredients Production, Consumption, Export, Import by Regions (2014-2021)
Chapter 6 Global High Potency Active Pharmaceutical Ingredients Production, Revenue (Value), Price Trend by Type
6.1 Global High Potency Active Pharmaceutical Ingredients Production and Market Share by Type (2014-2021)
6.2 Global High Potency Active Pharmaceutical Ingredients Revenue and Market Share by Type (2014-2021)
6.3 Global High Potency Active Pharmaceutical Ingredients Price by Type (2014-2021)
6.4 Global High Potency Active Pharmaceutical Ingredients Production Growth by Type (2014-2021)
Chapter 7 Global High Potency Active Pharmaceutical Ingredients Market Analysis by Application
7.1 Global High Potency Active Pharmaceutical Ingredients Consumption and Market Share by Application (2014-2021)
7.2 Global High Potency Active Pharmaceutical Ingredients Consumption Growth Rate by Application (2014-2021)
7.3 Market Drivers and Opportunities
7.3.1 Potential Applications
7.3.2 Emerging Markets/Countries
Chapter 8 High Potency Active Pharmaceutical Ingredients Manufacturing Cost Analysis
8.1 High Potency Active Pharmaceutical Ingredients Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of High Potency Active Pharmaceutical Ingredients
Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 High Potency Active Pharmaceutical Ingredients Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of High Potency Active Pharmaceutical Ingredients Major Manufacturers in 2020
9.4 Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change
Chapter 12 Global High Potency Active Pharmaceutical Ingredients Market Forecast (2021-2028)
12.1 Global High Potency Active Pharmaceutical Ingredients Production, Revenue Forecast (2021-2028)
12.2 Global High Potency Active Pharmaceutical Ingredients Production, Consumption Forecast by Regions (2021-2028)
12.3 Global High Potency Active Pharmaceutical Ingredients Production Forecast by Type (2021-2028)
12.4 Global High Potency Active Pharmaceutical Ingredients Consumption Forecast by Application (2021-2028)
12.5 High Potency Active Pharmaceutical Ingredients Price Forecast (2021-2028)
Chapter 13 Appendix
The Global High Potency Active Pharmaceutical Ingredients Market size is estimated to reach $21.41 Billion by 2026 growing at a CAGR of 9.1% over the forecast period of 2021-2026.
High Potency Active Pharmaceutical Ingredient (HPAPIs) are pharmacologically active compounds that are particularly effective. They have a very precise mechanism of action and are effective even at modest daily therapeutic dosages. High Potency Active Pharmaceutical Ingredient have the capacity to target specific disease cells and are thus employed in high-potency medication formulations.
Increasing demand of Oncology Drugs drives the market demand
BASF SE, Corden Pharma, Dr Reddy’s Laboratories, Pfizer Inc, Sun Pharmaceuticals, Sanofi S.A, Merck & Co, Novrartis, Roche, Cipla Inc among others
North America dominated the Global High Potency Active Pharmaceutical Ingredients Market with share of 35.9% in 2020. This might be linked to the region's growing demand for High Potency Active Pharmaceutical Ingredients, as well as the existence of important manufacturers and superior technical infrastructure.
Published On:Jan 2021
Base Year:2020
Historical Data:2017 - 2019
No of Pages:250
High Potency Active Pharmaceutical Ingredients Mar...
RD Code : HP22